Oruka’s psoriasis study supports planned Phase 3 trials after strong skin clearance

Oruka ($ORKA) reported positive 16-week results for ORKA-001 in the randomized Phase 2b EVERLAST-B psoriasis study. Among 46 patients assigned the highest dose, 61% achieved complete skin clearance, compared with none of 47 placebo recipients, meeting the primary endpoint. At least 90% improvement in psoriasis severity occurred in 86% of the high-dose group. The study enrolled 187 patients across four treatment groups.

Treatment-emergent adverse events affected 39% of high-dose recipients versus 43% with placebo; no serious events occurred in the high-dose group. Oruka plans to take the 600-milligram regimen into Phase 3 during the first half of 2027, subject to regulatory discussions. The findings strengthen its development case, while longer follow-up is still needed to establish durability and the proposed infrequent maintenance dosing.

Sources:

• ir.orukatx.com
• Issuer release via StockTitan